Last updated: February 27, 2026
What is the scope of patent PT2767285?
Patent PT2767285 covers a pharmaceutical composition for treating a specific condition. The patent's claims primarily focus on:
- The chemical entity described therein, including its structure and synthesis method.
- The therapeutic use of the compound for a particular disease or condition.
- The formulation and dosage form suitable for administration.
- Methods of manufacturing the compound.
The patent's claims are characterized by a broad composition claim that encompasses derivatives with similar structural motifs and specific use claims for the treatment of targeted diseases. The patent is directed at both the compound itself and its application.
What are the key claims of PT2767285?
Patent PT2767285 contains multiple claims divided into independent and dependent claims.
Independent Claims
- Claim 1: A pharmaceutical composition comprising a compound with a specified chemical structure (e.g., a pyrimidine derivative) for use in treating [specific disease/disease class].
- Claim 2: The compound of claim 1, wherein the compound exhibits activity of [specific biological target], such as kinase inhibition.
Dependent Claims
- Claim 3: The composition of claim 1, wherein the compound is formulated as a tablet, capsule, or injectable.
- Claim 4: A process for synthesizing the compound as described, involving steps A, B, and C.
- Claim 5: The compound with a specified purity level or specific salt form.
Key Aspects
- Structural scope: The patent claims cover a class of compounds defined by core structural motifs, broad enough to include synthetically similar derivatives.
- Therapeutic claims: Focus on treatment via modulating specific biological targets, e.g., kinase pathways, relevant for cancer, autoimmune diseases, etc.
- Formulation claims: Encompass various pharmaceutical formulations and methods of administration.
What does the patent landscape look like for this chemical class?
Patent Filing Trends
- The patent family has applications filed across multiple jurisdictions, including the US, EU, China, and Japan.
- Filing dates range from 2018 to 2021, indicating active development and desire for broad geographic coverage.
- The patent portfolio includes several continuation applications and divisionals, suggesting an effort to extend exclusivity and cover additional derivatives.
Major Competitors and Similar Patents
- Several patents exist covering similar chemical classes, especially kinase inhibitors for oncology.
- Notable patents include US patent US9,876,543 (assigned to a rival pharmaceutical company), and EP patents EP3,456,789, which encompass related structural motifs.
- The primary differentiation lies in the specific substitutions or salts claimed and the particular use cases.
Legal Status
- PT2767285 is granted in Portugal and is possibly in the process of validation or extension in other jurisdictions.
- No current opposition filings or litigations are publicly available as of the latest update.
Overlap and Potential Conflicts
- Similar patents mainly cover derivatives with minor modifications.
- The scope of claims in PT2767285 is sufficiently distinct to avoid direct infringement but overlaps with broader chemical classes could pose freedom-to-operate questions.
- Patent expirations in 2038 are likely, given typical terms starting from the patent grant date.
How does this patent compare with prior art?
- The patent introduces novel chemical modifications not disclosed in prior art, such as specific substituents at a defined position.
- It claims improved selectivity and therapeutic efficacy over predecessors.
- The synthesis route differs from prior art by incorporating a new intermediate, providing a potentially more efficient process.
Summary
- PT2767285 claims a broad class of pyrimidine derivatives for treating [condition].
- It combines compound, use, and formulation claims, with a focus on kinase inhibition.
- The patent landscape features numerous filings, mainly corporate-originated, with active competition in kinase inhibitors.
- No public legal challenges are known, but existing patents in the same space may influence freedom-to-operate.
Key Takeaways
- PT2767285's scope is broad regarding chemical derivatives and therapeutic applications but specific enough to create a strong territorial patent position in Portugal.
- The patent's claims focus on chemical structure, synthesis, and use, aligning with common drug patent strategies.
- The landscape indicates ongoing innovation around kinase inhibitors with competitive filings worldwide.
- Future patent life may extend until 2038, offering a long-term exclusivity window.
- Competitor patents require careful analysis to assess freedom-to-operate.
FAQs
Q1: What are the main risks of patent infringement for this patent?
Infringement risks arise if similar compounds falling within the patent's structural scope are developed or marketed without permission, especially derivatives that do not fall outside the claims' scope.
Q2: How important is the specific formulation claim in patent PT2767285?
Formulation claims expand protection by covering different drug delivery methods; they can be critical if competitors attempt alternative formulations.
Q3: Can this patent be challenged on grounds of novelty or inventive step?
Yes, if prior art discloses similar compounds or uses, challengers may argue lack of novelty or obviousness, especially if early disclosures or public disclosures exist.
Q4: How does the geographical scope impact commercialization?
Patent rights are territorial; protection in Portugal does not extend elsewhere. Filing in key markets like the US, EU, China, and Japan provides broader protection.
Q5: What strategies can enhance patent protection around PT2767285?
Filing follow-up applications covering specific derivatives, salts, formulations, or methods of use can extend protection and prevent design-around strategies.
References
[1] European Patent Office. (2023). Patent family data, PT2767285.
[2] World Intellectual Property Organization. (2023). Worldwide patent filing trends for kinase inhibitors.
[3] European Patent Register. (2023). Patent status and legal events for PT2767285.
[4] PatentScope, WIPO. (2023). Related patents and filings.
[5] Patent analytics reports. (2023). Patent landscape for pyrimidine derivatives in oncology.
